All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Fundamental significance of specific KRAS mutant types for prognosis of unresectable pancreatic cancer patients

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F16%3AN0000021" target="_blank" >RIV/26475821:_____/16:N0000021 - isvavai.cz</a>

  • Result on the web

    <a href="http://cancerres.aacrjournals.org/content/76/24_Supplement/A19" target="_blank" >http://cancerres.aacrjournals.org/content/76/24_Supplement/A19</a>

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    Fundamental significance of specific KRAS mutant types for prognosis of unresectable pancreatic cancer patients

  • Original language description

    Abstract at AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; May 12-15, 2016; Orlando, FL; The overall survival prognosis of patients in advanced unresectable stages of pancreatic ductal adenocarcinoma is poor, typically ranging from days to months from diagnosis. A prognostic marker would be useful in management of the disease guiding rational decisions between systemic or palliative therapy ensuring longest survival at an adequate quality of life. Due to its frequent occurrence in PDAC, prognostic value of KRAS mutation status has traditionally been studied. The results, however, were often contradictory. In the present work, we explore the role of individual KRAS mutant types in the assessment of prognosis. In addition, we explore KRAS mutation analysis from circulating tumor DNA (ctDNA) as a source material to eliminate biopsy-associated burden to the patient. FNA-biopsy followed by cytology evaluation and molecular testing of KRAS is feasible in routine management of pancreatic cancer patients. Differentiation of specific KRAS mutation types (above all the crucial Gly12Asp) is imperative for assessment of prognosis in the rational therapy decision process.

  • Czech name

  • Czech description

Classification

  • Type

    O - Miscellaneous

  • CEP classification

    EB - Genetics and molecular biology

  • OECD FORD branch

Result continuities

  • Project

    <a href="/en/project/NT13638" target="_blank" >NT13638: The clinical significance of epigenetic factors for improvement of diagnosis, assessment of prognosis and the risk of recurrence after curative resection for pancreatic cancer.</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2016

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů